Full Prescribing Information, Including BOXED WARNING
Read About Twirla
Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception
Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
Agile Therapeutics Reports Third Quarter 2020 Financial Results
Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020
Agile Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020
Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control
Agile Therapeutics Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Chief Medical Officer
Our pipeline reflects our commitment to bringing women the healthcare choices they deserve. All current Agile Therapeutics product and product candidates use our proprietary Skinfusion® Technology.
Commitment. Passion. Drive.
These are the qualities that make us who we are, from the top down.
©2020 Agile Therapeutics®. All Rights Reserved.